Vol. 5 (04) pp. 1891-1903 DOI: 10.21474/IJAR01/4027

EVALUATION OF YKL-40 AS A PROGNOSTIC MARKER IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS.

,
  • Clinical Pathology Department, Faculty of Medicine, Zagazig University.
  • Pathology Department College of Medicine, King Khalid University
15 Downloads 128 Views
Crossref

Download Full Paper (PDF)

Abstract

Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell disorder, characterized by arrested differentiation, inappropriate proliferation and survival of immature myeloid progenitors. The AML has the low survival rate. So, assessment of the prognostic factors in AML is very important. We aimed in this study to assess whether YKL-40 serum levels could be considered as a useful biomarker for the assessment of disease status progression and monitoring the response to treatment in patients with AML. Forty eight subjects were included in this study. They were classified into 2 groups; 24 apparently healthy adult subjects and 24 adult patients with newly diagnosed AML. Both groups were subjected to routine laboratory investigations and Estimation serum YKL-40 level by ELISA. There was a significant difference between levels of YKL-40 in control and patient group before induction therap. There was also a significant difference between YKL-40 level and the response to treatment and between its level and outcome during follow up period in responder patient group. Finally, by using Kaplan Meier curve; median time of DFS was significantly shorter in patients with YKL-40 ≥137 ng/ml compared to those with YKL-40 <137 ng/ml. It can be concluded that high serum level of YKL-40 was associated with bad response to treatment and confers poor outcome. Moreover, it could serve as valuable prognostic marker.

How to Cite This Article

Mohamed Eissa, and Amal Ahmad Zidan. (2017); EVALUATION OF YKL-40 AS A PROGNOSTIC MARKER IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS., International Journal of Advanced Research (IJAR), 5 (04), 1891-1903, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/4027

Corresponding Author

Mohamed Eissa
1- Clinical Pathology Department, Faculty of Medicine, Zagazig University 2- Pathology Department College of Medicine, King Khalid University

Article Analytics

References

  1. Russell NH. (1997): Biology of acute leukaemia. Lancet 1997. Jan 11; 349 (9045): 118-22.
  2. Estey E H. (2001): Prognostic factors in acute myeloid leukemia. Leukemia, 15:670-2.
  3. Kern W, Haferlach T, Schoch C (2003): Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood; 101:64-70.
  4. Cintin C., Johansen J.S., Christensen I. J., Price P.A., Sorensen S., and Nielsen H.J. (2002): High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95, 267?274.doi: 10.1002/cncr.10644.
  5. Johansen J.S., Drivsholm L., Price P.A. and Christensen I.J. (2004): High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer, 46, 333?340.
  6. De Ceuninck F., Gaufillier S., Bonnaud A., Sabatini M. and Lesur C (2001): YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminogly can synthesis in chondrocytes. Biochemical & Biophysical Research Communications 285: 926?931.
  7. Recklies A.D., White C. and Ling H. (2002): The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J365: 119?126.
  8. Varinder Jeet, Gregor Tevz, Melanie Lehman, Brett Hollier, and Colleen Nelson (2014): Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer. 2014 Oct; 21(5): 723?737.
  9. Volck B., Price P.A., Johansen J.S., S?rensen O., Benfield T., Calafat J., Nielsen H.J. and Borregaard N. (1998): YKL-40, a mammalian member of the bacterial chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351-60.
  10. Rehli M., Niller H.H., Ammon C., Langmann S., Schwarzfischer L., Andreesen R. and Krause S.W. (2003): Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. 278, 44058?44067.
  11. Cintin C, Johansen J S, Christensen I J, Price P A, S?rensen S, and Nielsen H J (1999): Serum YKL-40 and colorectal cancer. Br J Cancer. 1999 Mar; 79(9-10): 1494?1499.
  12. Johansen J.S., Christensen I.J., Riisbro R., Greenall M., Han C., Price P.A., Smith K., Brunner N and Harris Al (2003): High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat, 80:15-21.
  13. Johansen, J.S., Roslind, A., Palle, C., Christensen, I.J., Nielsen, H.J., Price, P.A. and Nielsen, D. (2006): Mosgaard, B. Serum YKL-40 levels in patients with cervical cancer are elevated compared to patients with cervical intraepithelial neoplasia and healthy controls. ASCO Ann. Meet. Proc., 24, 267, Abstract 5047. 68.
  14. Roslind A., Johansen J.S., Christensen I.J., Kiss K., Balslev E., Nielsen D.L., Bentzen J., Price P.A. and Andersen, E. (2008): High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int. J. Cancer, 122, 857?863.
  15. H?gdall E.V., Ringsholt M., H?gdall C.K., Christensen I.J., Johansen J.S., Kjaer S.K., Blaakaer J., Ostenfeld-M?ller L., Price P.A. and Christensen L.H. (2009): ?YKL-40 tissue expression and plasma levels in patients with ovarian cancer?. BMC Cancer 9: 8.
  16. Mylin A.K., Rasmussen T., Johansen J.S., Knudsen L.M., N?rgaard P.H., Lenhoff S., Dahl I.M.S. and Johnsen H.E. (2006): Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur. J. Hematol.77, 416?424.
  17. Anil K. Hurmale, Sudheer K. Choudhary, Satish K. Bhaskar and Suresh K. Jatawa, (2013): Overexpression of chitinase like protein YKL-40 in leukemia patients Hurmale et al. J. BioSci. Biotech.2 (3): 215-220.
  18. Kaplan E and Meier P (1958): Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
  19. Martin Bland J and Douglas Altman G (2004): The logrank test. BMJ. 2004 May 1; 328(7447): 1073.
  20. El Rassi F. and Arellano M. (2013): Update on Optimal Management of Acute Myeloid Leukemia. Clin Med Insights Oncol. 7: 181?197.
  21. Sievers E.L., Larso R.A., Stadtmauer E.A., Estey E., L?wenberg B. and Dombret (2001): Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19:3244-3254.
  22. Hwang K, Park CG and Jang S (2012): Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann. Hematol.:91:1541?1546.
  23. Ashraf M. El Hefni, Asmaa H E and Huda F. Ebian (2015): Prognostic Value of Human Chitinase 3-Like 1 in Adult Acute Myeloid Leukaemia.
  24. Weinblatt M.E. (2004): Acute myelocytic leukaemia, http://www. emedicine. com.
  25. Brunning RD, Matutes E and Flandrin G. (2001): Acute myeloid, leukaemias and myelodysplastic syndromes, therapy related. In: Jaffe ES, Harris NL, Stein H, et al., Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press. World Health Organization Classification of Tumour (3): 89-91.
  26. Bergmann O.J., Johansen J.S., Klausen T.W., Mylin A.K., Kristensen J.S., Kjeldsen E. and Johnsen H.E. (2005): High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin.Cancer Res. 11, 8644?8652.
  27. Fahmy R.G., Dass C.R., Sun L.Q., Chesterman C.N. and Khachigian L.M. (2003): Transcription factor Egr-1 supports F G F dependent angio Genesis during neovascularization and tumor growth. Nat Med 9:1026?1032.
  28. Faibish M., Francescone R., Bentley B., Yan W., and Shao R. (2011): AYKL-40 neutralizing antibody blockstum orangiogenesis and progression: a potential therapeutic agentin cancers. Mol. Cancer Therap. 10,742?751.
  29. Schmidt H., Johansen J.S., Gehl J., Geertsen P.F., Fode K. and von der Maase H. (2006): Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106, 1130?1139.
  30. Jensen B.V., Johansen J.S., and Price P.A. (2003): High levels of serum HER-2/neuandYKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin.Cancer Res. 9, 4423?4434.
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.